In-vitro Models and Studies

LIDE complements its in vivo expertise with a diverse suite of in vitro assays, providing scalable, mechanistic, and cost-effective platforms to support oncology drug discovery. From traditional 2D cell lines to advanced patient-derived 3D organoids and immune co-culture systems, our in vitro solutions help bridge the gap between bench research and translational relevance.

Commercial Cell Lines

Commercial cell lines a well established and a widely used for early validation studies. LIDE has a growing bank ready for client application.

· 220+ human cancer cell lines available.
· Includes luciferase-tagged and resistant variants
· Cost effective and fast turnaround time

Conditionally Reprogrammed (CR) Cells

LIDE’s CR cells maintains both inter- and intra-tumoral heterogeneity, offering a better option than commercially available cell lines

· 100+ CR lines derived from patient tumors
· Many with matching PDX models for subsequent in-vivo validation
· Cost effective while maintaining translatability

Learn More ›

3D Spheroids & Organoids

Designed for speed, scalability, and biological fidelity, our 3D spheroid and scaffold-based organoid assays allow researchers to model complex tumor biology with greater accuracy than 2D cultures.

· Frozen PDXO Biobank – 225 models across 21 cancer types, readily available with consistent post-thaw performance
· Many with matching PDX models for subsequent in-vivo validation
· More cost effective than similar PDX studies

Learn More ›

ex vivo model

Co-Culture Assays for IO

Model real-world tumor biology by combining multiple relevant cell types (e.g. tumor, stromal, and immune cells) within the same assay

· Co-culture with stromal and/or immune cells
· Use PDX-derived organoids with matched immune cells for patient-specific IO testing
· Bioluminescence, imaging cytometry, flow cytometry, and spatial analysis for readouts

Learn More ›